GENinCode (LSE:GENI) Forward Dividend Yield %: 0.00% (As of Jun. 29, 2026)


What is GENinCode Forward Dividend Yield %?

GENinCode LSE:GENI +5.56% Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. The stock has 4 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, GENinCode ranks worse than 1612901.61% on this metric.

As of today (2026-06-29), the Forward Annual Dividend Yield of GENinCode is 0.00%.

As of today (2026-06-29), the Trailing Annual Dividend Yield of GENinCode is 0.00%.

LSE:GENI's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.84
* Ranked among companies with meaningful Forward Dividend Yield % only.

GENinCode's Dividends per Share for the six months ended in Dec. 2025 was £0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

GENinCode  (LSE:GENI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

GENinCode Forward Dividend Yield % Related Terms

LSE:GENI vs TMO, DHR, IDXX: Forward Dividend Yield % Comparison

For the Diagnostics & Research subindustry, GENinCode's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GENinCode Forward Dividend Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where GENinCode's Forward Dividend Yield % falls into.


GENinCode Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
GENinCode (LSE:GENI) has a Forward Dividend Yield % of 0.00% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on GENinCode and its competitors. According to the industry distribution chart, GENinCode ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry.
Is GENinCode's Forward Dividend Yield % too high?
GENinCode's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, GENinCode ranks #999999 out of 62 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does GENinCode's Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, GENinCode ranks #999999 out of 62 companies for Forward Dividend Yield %. This places GENinCode in the lower half of its industry. The industry median Forward Dividend Yield % is 1.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.84, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on GENinCode and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GENinCode's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GENinCode stock overvalued right now?
Based on GuruFocus' analysis, GENinCode (LSE:GENI) is currently considered Possible Value Trap. The stock's GF Value™ is £0.04, compared to a current price of £0.01 — trading 76.3% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For GENinCode (LSE:GENI), the current Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GENinCode Business Description

Address Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP
GENinCode PLC principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes. The company has one operating segment. The company has presence in Spain, UK, United States, Italy, Germany, and Rest of World. The company generates majority of revenue from Spain. Its commercial products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode.